Vemurafenib-induced interface dermatitis manifesting as radiation-recall and a keratosis pilaris-like eruption.

Abstract

Vemurafenib is a specific inhibitor of the V600E mutated BRAF protein kinase used for the treatment of unresectable or metastatic melanoma harboring this mutation. Multiple predictable side effects have been described with use of this targeted therapy, and implicate BRAF and mitogen activated protein kinase (MAPK) signaling pathways in their pathogenesis. Herein, we report the novel finding of an interface dermatitis in radiation recall and a keratosis pilaris-like clinical reaction in a patient treated with vemurafenib.

• Authors: Inbal Braunstein, Tara C Gangadhar, Rosalie Elenitsas, Emily Y Chu
• Journal: Journal of cutaneous pathology (J Cutan Pathol) Vol. 41 Issue 6 Pg. 539-43 (Jun 2014) ISSN: 1600-0560 [Electronic] United States
• PMID: 24517243 (Publication Type: Case Reports, Journal Article)
• Copyright: © 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Chemical References

• Antineoplastic Agents
• Indoles
• Sulfonamides
• Vemurafenib

Topics

• Abnormalities, Multiple (chemically induced, pathology)
• Adult
• Antineoplastic Agents (adverse effects, therapeutic use)
• Darier Disease (chemically induced, pathology)
• Drug Eruptions (pathology)
• Eyebrows (abnormalities, pathology)
• Humans
• Indoles (adverse effects, therapeutic use)
• Male
• Melanoma (drug therapy, pathology, surgery)
• Skin Neoplasms (drug therapy, pathology, surgery)
• Sulfonamides (adverse effects, therapeutic use)
• Vemurafenib